Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting

Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains the standard frontline regimen for diffuse Large B –cell lymphoma, the optimal chemotherapy regimen for frontli...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jiangning, Xu, Zhenshu, Liu, Delong, Lu, Quanyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480919/
https://www.ncbi.nlm.nih.gov/pubmed/22913602
http://dx.doi.org/10.1186/1475-2867-12-38

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480919/
https://www.ncbi.nlm.nih.gov/pubmed/22913602
http://dx.doi.org/10.1186/1475-2867-12-38

Ejemplares similares